Press release

Datesort descending Press release
03/11/2014 Inventiva receives positive opinion on orphan drug designation in Systemic Sclerosis for IVA 337
02/12/2014 Inventiva receives another positive opinion on orphan drug designation in the European Union for IVA337 – for Idiopathic Pulmonary Fibrosis
09/02/2015 SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies
03/12/2015 European Eurostars funding received for epigenetics program NSD2
28/01/2016 IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge
25/02/2016 Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress
31/05/2016 Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
11/07/2016 Inventiva announces the registration of its IPO document de base
19/09/2016 Inventiva Announces Receipt of €2.3 million in Grant Funding for YAP/TEAD Protein Research Program
03/01/2017 Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
13/01/2017 Inventiva files an update to its document de base with a view to its initial public offering
02/02/2017 Inventiva launches its initial public offering on the regulated market of Euronext Paris
14/02/2017 Inventiva raises €48 million in a successful initial public offering on Euronext Paris
17/03/2017 Inventiva’s confirms the success of its IPO. Over-allotment option partially exercised
17/03/2017 Inventiva Announces the Implementation of a Liquidity Contract with Oddo & Cie (only in french)
27/03/2017 Inventiva: acceleration of the clinical development activities and consolidation of the financial position in 2016
10/04/2017 Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)
20/04/2017 Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)
15/05/2017 Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337
30/05/2017 Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board